we compare NAD, NMN, and NR, different routes of administration, their safety, and bioavailability
For licensing inquiries, please contact [email protected]
Express or implied claims that FDA approved, evaluated, or reviewed the compounded product for safety, effectiveness, or quality
A study in JAMAs Ophthalmology Journal found that those who have used GLP-1 drugs are at a higher risk of developing NAION than those who were prescribed alternative diabetes control medications
That is, compared to insulin, 57 and 30 patients would need to be treated with a GLP-1RA for a mean of 2.3 years to prevent one case of all-cause mortality and hospitalized hypoglycemia, respectively, which would cost US$54,851 and US$29,115 per case of all-cause mortality and hospitalized hypoglycemia prevented, respectively, from the payer perspective, and would save US$19,391 and US$10,293, respectively, from the healthcare sector perspective
Eating makes your insulin spike, especially if you eat carbs
